| Prednisolone(N = 21) | Placebo(N = 16) | Prednisolone versus placebo |
| Mean AUC(SD) | Difference in mean AUC(95%CI);Pvalue |
Cough | 36.29 (25.89) | 34.38 (24.71) | |
Unadjusted | | | 1.91 (–15.20 to 19.01); P = 0.82 |
Adjusted for baselinea | | | 2.27 (–15.22 to 19.75); P = 0.79 |
Phlegm | 20.60 (19.97) | 30.69 (25.42) | |
Unadjusted | | | –10.09 (–25.23 to 5.04); P = 0.19 |
Adjusted for baselineb | | | –10.35 (–26.18 to 5.48); P = 0.19 |
Shortness of breath | 12.45 (16.13) | 17.56 (19.79) | |
Unadjusted | | | –5.11 (–17.10 to 6.88); P = 0.39 |
Adjusted for baselineb | | | –3.64 (–15.56 to 8.29); P = 0.54 |
Wheeze | 15.12 (16.4) | 16.13 (18.93) | |
Unadjusted | | | –1.01 (–12.82 to 10.80); P = 0.86 |
Adjusted for baselineb | | | –2.10 (–13.75 to 9.54); P = 0.72 |
Blockedorrunny nose | 15.67 (20.78) | 20.15 (25.66) | |
Unadjusted | | | –4.49 (–19.99 to 11.00); P = 0.56 |
Adjusted for baselineb | | | –4.24 (–19.83 to 11.34); P = 0.58 |
Chest pain | 10.33 (14.50) | 5.91 (8.52) | |
Unadjusted | | | 4.43 (–3.85 to 12.71); P = 0.29 |
Adjusted for baselineb | | | 5.07 (–2.74 to 12.88); P = 0.17 |
Fever | 3.48 (6.36) | 5.53 (14.08) | |
Unadjusted | | | –2.06 (–9.06 to 4.95); P = 0.56 |
Adjusted for baselineb | | | –2.91 (–9.25 to 3.43); P = 0.36 |
Muscle ache | 13.74 (24.87) | 8.31 (14.46) | |
Unadjusted | | | 5.43 (–8.75 to 19.60); P = 0.44 |
Adjusted for baselineb | | | 5.84 (–8.45 to 20.13); P = 0.41 |
Headache | 11.64 (24.67) | 6.88 (15.84) | |
Unadjusted | | | 4.77 (–9.61 to 19.14); P = 0.51 |
Adjusted for baselineb | | | 4.91 (–9.54 to 19.36); P = 0.50 |
Sleep disturbance | 20.29 (24.84) | 17.94 (24.07) | |
Unadjusted | | | 2.35 (–14.17 to 18.86); P = 0.78 |
Adjusted for baselineb | | | 3.23 (–13.67 to 20.12); P = 0.70 |
Feeling unwell | 19.86 (27.79) | 17.19 (22.54) | |
Unadjusted | | | 2.67 (–14.62 to 19.96); P = 0.76 |
Adjusted for baselineb | | | 1.29 (–15.35 to 17.93); P = 0.88 |
Activity disturbance | 10.14 (13.16) | 10.59 (20.64) | |
Unadjusted | | | –0.45 (–11.75 to 10.85); P = 0.94 |
Adjusted for baselineb | | | –0.15 (–11.56 to 11.27); P = 0.98 |
| Median duration (IQR) | HR(95%CI);Pvalue |
Duration of moderate-badorworse cough (censored at56days)c | 3 (2–6) | 3 (1–6) | |
Unadjusted | | | 1.01 (0.50 to 2.05); P = 0.99 |
Adjusted for baselineb | | | 1.01 (0.49 to 2.04); P = 0.99 |
Duration of any cough (censored at56days)c | 18 (14–31) | 13 (6–26) | |
Unadjusted | | | 0.68 (0.32 to 1.46); P = 0.32 |
Adjusted for baselineb | | | 0.69 (0.32 to 1.48); P = 0.35 |
Duration of abnormal peak flowc | 24 (4–n/a)d | 6 (4–n/a)d | |
Unadjusted | | | 0.45 (0.17 to 1.24); P = 0.12 |
Adjusted for baselinea | | | 0.51 (0.18 to 1.42); P = 0.21 |
Adjusted for baselinee | | | 0.79 (0.22 to 2.79); P = 0.71 |
| n (%) | OR(95%CI);Pvalue |
Consumption of antibiotics up to7days | 1 (4.8) | 1 (6.3) | |
Unadjusted | | | 0.75 (0.04 to 12.99); P = 0.84 |
Adjusted for delayed script | | | 0.74 (0.04 to 13.48); P = 0.84 |
Consumption of antibiotics up to28daysf | 2 (16.7) | 3 (33.3) | |
Unadjusted | | | 0.46 (0.07 to 3.12); P = 0.42 |
Adjusted for delayed script | | | 0.38 (0.04 to 3.27); P = 0.38 |
Participant agrees trial tablets helped them feel betterf | 6 (33.3) | 6 (40.0) | |
Unadjusted | | | 0.75 (0.18 to 3.11); P= 0.69 |
Participant agrees they would take trial tablets in futuref | 9 (50.0) | 9 (60.0) | |
Unadjusted | | | 0.67 (0.17 to 2.67); P = 0.57 |
Adverse eventsg | | | |
01>1 | 16 (72.7)6 (27.3)0 (0.0) | 14 (77.8)4 (22.2)0 (0.0) | |
Unadjusted | | | 1.31 (0.31 to 5.62); P = 0.72g |
Adjusted for baselineh | | | 1.17 (0.25 to 5.38); P = 0.84g |